1
|
Beenken A and Mohammadi M: The FGF family:
Biology, pathophysiology and therapy. Nat Rev Drug Discov.
8:235–253. 2009. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Mohammadi M, Olsen SK and Ibrahimi OA:
Structural basis for fibroblast growth factor receptor activation.
Cytokine Growth Factor Rev. 16:107–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rusnati M and Presta M: Fibroblast growth
factors/fibroblast growth factor receptors as targets for the
development of anti-angiogenesis strategies. Curr Pharm Des.
13:2025–2044. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Saxena R and Dwivedi A: ErbB family
receptor inhibitors as therapeutic agents in breast cancer: Current
status and future clinical perspective. Med Res Rev. 32:166–215.
2012. View Article : Google Scholar
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Yamamoto M, Hosoda M, Nakano K, et al: p53
accumulation is a strong predictor of recurrence in estrogen
receptor-positive breast cancer patients treated with aromatase
inhibitors. Cancer Sci. 105:81–88. 2014. View Article : Google Scholar
|
7
|
Choi SY, Chang YW, Park HJ, Kim HJ, Hong
SS and Seo DY: Correlation of the apparent diffusion coefficiency
values on diffusion-weighted imaging with prognostic factors for
breast cancer. Brit J Radiol. 85:E474–E479. 2012. View Article : Google Scholar
|
8
|
van de Vijver MJ: Molecular tests as
prognostic factors in breast cancer. Virchows Arch. 464:283–291.
2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Donegan WL: Tumor-related prognostic
factors for breast cancer. CA Cancer J Clin. 47:28–51. 1997.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Dickson C, Spencer-Dene B, Dillon C and
Fantl V: Tyrosine kinase signalling in breast cancer: Fibroblast
growth factors and their receptors. Breast Cancer Res. 2:191–196.
2000. View Article : Google Scholar
|
11
|
Grose R and Dickson C: Fibroblast growth
factor signaling in tumorigenesis. Cytokine Growth Factor Rev.
16:179–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh
N, Linhardt RJ and Mohammadi M: Biochemical analysis of pathogenic
ligand-dependent FGFR2 mutations suggests distinct
pathophysiological mechanisms for craniofacial and limb
abnormalities. Hum Mol Genet. 13:2313–2324. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Penault-Llorca F, Bertucci F, Adélaïde J,
Parc P, Coulier F, Jacquemier J, Birnbaum D and deLapeyrière O:
Expression of FGF and FGF receptor genes in human breast cancer.
Int J Cancer. 61:170–176. 1995. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wu XP, Huang HX, Wang C, Lin S, Huang Y,
Wang Y, Liang G, Yan Q, Xiao J, Wu J, et al: Identification of a
novel peptide that blocks basic fibroblast growth factor-mediated
cell proliferation. Oncotarget. 4:1819–1828. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: Cyclin D1: Normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Pagès G, Lenormand P, L'Allemain G,
Chambard JC, Meloche S and Pouysségur J: Mitogen-activated protein
kinases p42mapk and p44mapk are required for fibroblast
proliferation. Proc Natl Acad Sci USA. 90:8319–8323. 1993.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Xia X, Cheng A, Lessor T, Zhang Y and
Hamburger AW: Ebp1, an ErbB-3 binding protein, interacts with Rb
and affects Rb transcriptional regulation. J Cell Physiol.
187:209–217. 2001. View
Article : Google Scholar : PubMed/NCBI
|
18
|
Maga G and Hubscher U: Proliferating cell
nuclear antigen (PCNA): A dancer with many partners. J Cell Sci.
116:3051–3060. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang JT and Liu Y: Use of comparative
proteomics to identify potential resistance mechanisms in cancer
treatment. Cancer Treat Rev. 33:741–756. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kandel E: Tumor-associated oncogenes go on
(phage) display. Oncotarget. 1:84–85. 2010. View Article : Google Scholar
|
21
|
Ionov Y: A high throughput method for
identifying personalized tumor-associated antigens. Oncotarget.
1:148–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Bae DG, Kim TD, Li G, Yoon WH and Chae CB:
Anti-Flt1 peptide, a vascular endothelial growth factor receptor
1-specific hexapeptide, inhibits tumor growth and metastasis.
Clinical Cancer Res. 11:2651–2661. 2005. View Article : Google Scholar
|
23
|
Yardley DA, Hart L, Bosserman L, Salleh
MN, Waterhouse DM, Hagan MK, Richards P, DeSilvio ML, Mahoney JM
and Nagarwala Y: Phase II study evaluating lapatinib in combination
with nab-paclitaxel in HER2-overexpressing metastatic breast cancer
patients who have received no more than one prior chemotherapeutic
regimen. Breast Cancer Res Treat. 137:457–464. 2013. View Article : Google Scholar :
|
24
|
Knights V and Cook SJ: De-regulated FGF
receptors as therapeutic targets in cancer. Pharmacol Ther.
125:105–117. 2010. View Article : Google Scholar
|
25
|
Li Y, Hively WP and Varmus HE: Use of
MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast
cancer. Oncogene. 19:1002–1009. 2000. View Article : Google Scholar : PubMed/NCBI
|
26
|
Turnbull C, Ahmed S, Morrison J, et al:
Genome-wide association study identifies five new breast cancer
susceptibility loci. Nat Genet. 42:504–547. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Roy D and Calaf GM: Allelic loss at
chromosome 11q13 alters FGF3 gene expression in a human breast
cancer progression model. Oncol Rep. 32:2445–2452. 2014.PubMed/NCBI
|
28
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
29
|
Welsh CF, Roovers K, Villanueva J, Liu YQ,
Schwartz MA and Assoian RK: Timing of cyclin D1 expression within
G1 phase is controlled by Rho. Nat Cell Biol. 3:950–957. 2001.
View Article : Google Scholar : PubMed/NCBI
|